Cynthia L. Palmer

机构：Pfizer (United States), Université Bourgogne Franche-Comté

发表论文 41 篇 · 总被引 1079 次 · h-index 10

代表论文

• Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations (2014 · Journal of Medicinal Chemistry · 被引 593)
• Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib (2014 · Journal of Medicinal Chemistry · 被引 118)
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety (2025 · Cancer Cell · 被引 61)
• Best Practice Implementation: Lessons Learned from 20 Partnerships (2007 · The Joint Commission Journal on Quality and Patient Safety · 被引 22)
• Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 (2012 · Molecular Cancer Therapeutics · 被引 9)
• PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2 (2007 · Cancer Research · 被引 9)